Pioneering biomarker technologies for Cancer therapies

Our biomarkers are used to identify the right patient, the right drug and the right dose.

Biomarker tests


magnifying

Using our biomarker tests provides more effective treatment for patients and economic savings for the healthcare system. Our colorectal cancer tests are validated using thousands of patient samples and are set to transform the current treatment pathway.

Biomarker platforms


testtubes

Our companion diagnostic biomarker platforms are used to discover biomarkers which improve both the benefit and risk profiles of pipeline drugs.

CancerNav®

A functional genome-wide screen to discover companion diagnostic biomarkers that predict efficacy.

ToxNavTM

A genome-wide screen using the principles of toxgnostics to discover biomarkers that predict drug specific side-effects.

We are looking to partner with leading drug development companies for companion diagnostic development.

Contact us

We have reached a crossroads in cancer treatment, where we can apply innovative tests on the patient’s blood and tumour tissue to select which patients need chemotherapy, what drugs will be most effective and what is a safe dose, reducing the risk of side effects. Our portfolio of biomarker tests allows us to make a step change in the treatment of early stage colorectal cancer, a disease affecting 1.2 million new patients every year, presenting a major global burden of morbidity and mortality.”

Prof. David Kerr CBE MD DSc FRCP (Glas, Lon, Edin) FRCGP FMedSci.

October 9, 2017

Oxford Cancer Biomarkers appoints David Browning as its Chief Executive Officer and Board member

Oxford, UK, 9th October 2017 Oxford Cancer Biomarkers has appointed healthcare industry leader David Browning as Chief Executive Officer and member of the Board. This represents an important milestone for the company which aims to benefit cancer patients through the implementation of advanced precision oncology diagnostics to improve screening and enable better treatment decisions for people... more

September 4, 2017

MBM and OCB announce the set-up of joint laboratories in Ningbo Meishan and Oxford at the 3rd China Medical Devices Int’l Summit on 26th August 2017

Oxford, UK, 1st September 2017 The announcement, at the 3rd China Medical Devices Int’l Summit, follows the signing in March 2017 of a memorandum of strategic collaboration between Oxford Cancer Biomarkers (OCB) and Ningbo My-BioMed Biotechnology Co. Ltd (MBM). MBM and OCB announced as part of ‘the Belt and Road Medical Cooperation Initiative’ that both parties will establish joint... more
doctor

Partnering with Pharmaceutical companies

We partner with leading pharmaceutical companies to develop cost effective companion biomarkers for pipeline drugs using our patented technology.

Learn more